M-CPP and Fenfluramine in Cocaine Addicts - 3

This study has been completed.
Sponsor:
Collaborator:
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00000314
First received: September 20, 1999
Last updated: August 16, 2005
Last verified: December 2002
  Purpose

The purpose of this study is to evaluate predictive value of M-CPP and fenfluramine challenges for outcome.


Condition Intervention Phase
Cocaine-Related Disorders
Drug: M-CPP
Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: To Study Predictive Values of M-CPP and Fenfluramine in Cocaine Addicts

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Drug use
  • Hospitalization, arrests, jail, employment, psychiataric symptoms

Estimated Enrollment: 0
  Eligibility

Ages Eligible for Study:   25 Years to 50 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Please contact site for information.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00000314

Locations
United States, New York
VA Medical Center
Brooklyn, New York, United States, 11209
Sponsors and Collaborators
Investigators
Principal Investigator: Laure Buydens-Branchey, M.D. Department of Veterans Affairs
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00000314     History of Changes
Other Study ID Numbers: NIDA-09468-3, R01-09468-3
Study First Received: September 20, 1999
Last Updated: August 16, 2005
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Cocaine-Related Disorders
Substance-Related Disorders
Mental Disorders
Fenfluramine
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors

ClinicalTrials.gov processed this record on April 17, 2014